Create Free Account

By creating account you will get access to hot stocks & personalised emails

Universal Biosensors Inc.

Healthcare AU UBI

0.135AUD
-0.005(3.57%)

Last update at 2024-05-16T00:09:00Z

Day Range

0.140.14
LowHigh

52 Week Range

0.130.32
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -29.90539M -10.50694M -7.63802M -6.16376M 41.92M
Minority interest - - - - -
Net income -26.85455M -10.30178M -7.66696M -4.84628M 37.56M
Selling general administrative 11.08M 5.61M 5.88M 6.98M 7.00M
Selling and marketing expenses - - - - -
Gross profit 2.14M 2.11M 0.62M 3.33M 66.95M
Reconciled depreciation 2.79M 2.57M 2.43M 1.51M 2.11M
Ebit -19.07844M -10.98754M -9.73194M -10.39982M 44.13M
Ebitda -15.97130M -8.69794M -7.13305M -9.79042M 46.24M
Depreciation and amortization 3.11M 2.29M 2.60M 0.61M 2.11M
Non operating income net other - - - - -
Operating income -19.07844M -10.98754M -9.73194M -10.39982M 46.42M
Other operating expenses 23.60M 16.77M 12.93M 17.30M 23.03M
Interest expense 0.02M 0.12M 0.15M 4.79M 2.21M
Tax provision -3.05084M 0.00000M 0.00000M -1.31748M 4.35M
Interest income 0.05M 0.05M 0.29M 1.38M 1.14M
Net interest income 0.16M -0.07196M 0.14M 0.83M -2.50008M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.05084M -0.20516M 0.03M -1.31748M 4.35M
Total revenue 4.52M 5.78M 3.20M 6.90M 69.46M
Total operating expenses 21.22M 13.09M 10.36M 13.73M 20.52M
Cost of revenue 2.39M 3.67M 2.58M 3.57M 2.51M
Total other income expense net -10.82695M 0.48M 2.09M 4.24M -4.50578M
Discontinued operations - - - - -
Net income from continuing ops -26.85455M -10.50694M -7.63802M -4.84628M 37.56M
Net income applicable to common shares -26.85455M -10.50694M -7.63802M -4.84628M 37.56M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 30.12M 46.15M 44.50M 56.38M 62.66M
Intangible assets - 0.00000M 12.65M 14.29M 15.93M
Earning assets - - - - -
Other current assets 1.45M 0.82M 4.54M 3.60M 3.46M
Total liab 10.61M 20.05M 16.89M 18.40M 17.27M
Total stockholder equity 19.51M 26.09M 27.61M 37.98M 45.39M
Deferred long term liab - - - - -
Other current liab 2.93M 11.96M 8.36M 6.36M 6.08M
Common stock 0.02M 0.02M 0.02M 0.02M 93.41M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -99.42035M -92.67878M -65.82423M -55.31730M -48.02101M
Other liab - 2.97M 5.80M 5.81M 7.10M
Good will - - - - -
Other assets - 0.41M 0.85M 2.32M 4.91M
Cash 10.28M 25.98M 15.32M 23.56M 32.29M
Cash and equivalents - 25.98M 15.32M 23.56M 30.23M
Total current liabilities 5.95M 13.09M 9.40M 8.96M 10.16M
Current deferred revenue 0.04M 0.03M 0.04M 1.63M 2.68M
Net debt -5.30394M -21.14885M -13.06230M -19.40169M -32.28500M
Short term debt 1.75M 0.83M 0.57M 0.52M 0.78M
Short long term debt 0.91M 0.07M 0.06M - -
Short long term debt total 4.97M 4.83M 2.26M 4.16M -
Other stockholder equity 119.24M 119.04M 93.74M 93.57M 0.34M
Property plant equipment - 9.06M 6.15M 8.38M 4.75M
Total current assets 22.00M 36.67M 24.85M 31.40M 37.07M
Long term investments - - - - -
Net tangible assets - 26.09M 14.96M 23.69M 29.47M
Short term investments - - - - -
Net receivables 5.90M 5.71M 0.48M 0.07M 0.12M
Long term debt - - 0.00000M 0.04M -
Inventory 4.38M 3.14M 2.14M 1.88M 1.08M
Accounts payable 1.24M 0.27M 0.44M 0.45M 0.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.33217M -0.29171M -0.32329M -0.29307M -0.34174M
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.09M 0.41M 0.85M 2.32M 4.91M
Deferred long term asset charges - - - - -
Non current assets total 8.12M 9.47M 19.65M 24.99M 25.59M
Capital lease obligations 4.06M 4.76M 2.19M 4.12M -
Long term debt total - 0.06M 0.00000M 0.04M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.56514M -0.66458M -0.37220M -10.28124M -0.35679M
Change to liabilities 0.16M 0.35M -2.55044M -3.84730M 0.86M
Total cashflows from investing activities -1.56514M -0.66458M -0.37220M -10.28124M -0.35679M
Net borrowings -0.00552M 0.02M 0.04M 0.04M -20.68965M
Total cash from financing activities 25.01M 0.10M 0.04M 0.00340M -20.94607M
Change to operating activities -0.97718M -1.14084M -0.31889M -2.75093M 0.13M
Net income -26.85455M -10.50694M -7.63802M -4.84628M 37.56M
Change in cash 8.73M -9.95590M -9.13779M 25.06M -17.36185M
Begin period cash flow 18.10M 28.06M 37.19M 12.13M 29.50M
End period cash flow 26.82M 18.10M 28.06M 37.19M 12.13M
Total cash from operating activities -14.70215M -9.89662M -8.29114M 33.24M 1.76M
Issuance of capital stock 24.97M - - 0.00340M -
Depreciation 2.79M 2.57M 2.43M 1.51M 2.11M
Other cashflows from investing activities - 0.00000M 0.01M 0.00338M 0.09M
Dividends paid - - - - -
Change to inventory -0.99868M -0.26365M -0.80179M 0.04M -0.08233M
Change to account receivables -0.47284M -0.40883M 0.04M 50.09M -45.81229M
Sale purchase of stock 25.02M 0.08M 0.00000M 0.00340M 0.00000M
Other cashflows from financing activities 1.05M -0.66458M -0.37220M -10.28124M -0.25641M
Change to netincome 11.65M -0.49803M 0.54M -2.60164M 2.64M
Capital expenditures 1.57M 0.66M 0.39M 10.31M 0.45M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.28692M -1.45837M -3.62757M 39.18M -40.55555M
Stock based compensation 0.32M 0.09M 0.17M -0.42175M 0.32M
Other non cash items 11.33M -0.59047M 0.37M -2.17989M 2.32M
Free cash flow -16.26730M -10.56120M -8.67818M 22.93M 1.32M

Fundamentals

  • Previous Close 0.14
  • Market Cap32.40M
  • Volume12219
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.81684M
  • Revenue TTM6.81M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 2.14M
  • Diluted EPS TTM-0.03

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
UBI
Universal Biosensors Inc.		 -0.005 3.57% 0.14 - - 6.98 2.37 6.18 -7.1305
COH
Cochlear Ltd		 5.91 1.78% 337.78 63.82 46.30 9.75 11.76 9.62 36.63
PNV
Polynovo Ltd		 0.04 2.08% 2.21 - 140.85 17.37 21.49 17.51 647.42
AVR
Anteris Technologies Ltd		 0.01 0.05% 20.23 - - 104.23 14.98 95.15 -5.9152
AVH
Avita Therapeutics Inc		 -0.09 3.45% 2.52 - - 8.59 5.71 6.72 -10.0538

Reports Covered

Stock Research & News

View All

Profile

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.

Universal Biosensors Inc.

1 Corporate Avenue, Rowville, VIC, Australia, 3178

Key Executives

Name Title Year Born
Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin Chief Exec. Officer 1966
Mr. Salesh Balak B.A., BA, C.A., CA CFO & Company Sec. 1969
Mr. Nicholas Bliesner Head of Operations NA
Mr. Steven Burgess Head of Sales & Marketing NA
Mr. Luke Cossins B.Sc., M.B.A. Head of R&D NA
Ms. Ann Chew B.Com., CPA Head of People Strategy & Culture NA
Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin Chief Executive Officer 1966
Mr. Salesh Balak B.A., BA, C.A., CA CFO & Company Secretary 1969
Mr. Luke Cossins B.Sc., M.B.A. Head of Research & Development NA
Ms. Ann Chew B.Com., CPA, CIA Head of People Strategy & Culture NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.